PD-L1 22C3 (NSCLC)

Description- This is a FDA-approved test which helps in prediction of response to pembrolizumab (KEYTRUDA) for patients with non-small cell lung cancer (NSCLC)

Methodology: Immunohistochemistry

TAT: 3-5 days

Specimen Preparation
Collect - tissue /or cell
Specimen Preparation- formal fix (10 % neutral buffered formalin) and paraffin enter specimen (FFPE specimens square measure needed). shield paraffin block or slides from uncontrolled heat. Transport tissue block or five unstained (3-micron thick sections), charged slides during a tissue transport kit. (Min: a pair of slides). If causing precut slides, don't over heat it.
Storage/Transport Temperature- At temperature or cold. Transport it in cooled instrumentation throughout weather.

Unacceptable Conditions- i) Tumor types that have FDA approval for PD-L1 22C3 testing with combined positive score (CPS).

ii)Paraffin block with no tumor tissue remaining.

iii) Specimens fixed in any fixative other than 10 percent neutral buffered formalin. I iv) Decalcified specimens.

v) Specimens with fewer than 100 viable tumor cells.

Remark- Include surgical pathology report and indicate tissue site with the test order.

Stability- Slides: Ambient: 6 months (Must be stored in the dark); Refrigerated: 6 months (Must be stored in the dark); Frozen: Unacceptable
Paraffin Block: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable